CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seaside Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted US patent No: 8,143,311, titled “Methods of Treating Fragile X Syndrome and Autism,” which covers the use of the Company’s lead product, STX209, for the improvement of social and communication functions in autism. Seaside’s lead clinical candidate, STX209, is an oral selective gamma-aminobutyric acid-B (GABA-B) receptor agonist and is currently being studied in a Phase 2b study in autism spectrum disorders and two Phase 3 studies in fragile X syndrome.
